The authors compiled somatic variant data from more than 4,000 tumors across 15 tissue types and surveyed mutation density at transcription factor binding sites. They reported analyses for binding motifs representing 655 TFs organized into 276 motif clusters. The study team assessed enrichment at single-nucleotide resolution, explicitly accounting for both sequence-dependent and local background variation in mutation rates. Nearly one third of the analyzed pairs with adequate mutation counts showed statistically significant enrichment at one or more binding-site positions. Enrichment was most pervasive in melanoma, though the cohort showed detectable enrichment in every tissue type examined; the identity of affected TFs and the positions within their motifs differed across tissues.
This work maps where somatic mutations accumulate relative to TF binding motifs, not only reporting that enrichment exists but cataloging the specific TFs and motif positions where excess mutations were observed. The abstract does not provide exact per-cluster sample sizes or the numerical thresholds the authors used to define ‘‘sufficient mutation counts’’; those details are contained in the full manuscript or supplementary files and are not repeated here.
The study team observed that TFs with higher expression levels were more likely to show mutation enrichment at their binding sites than lowly expressed TFs. This association suggests that active binding — as inferred by expression — may increase the local probability of mutation, either by altering DNA damage formation or by interfering with DNA repair processes at occupied sites. Authors noted this expression–enrichment pattern as consistent with a model in which protein–DNA interactions modulate mutagenesis, but the abstract does not specify whether expression was measured from matched tumor RNA-seq, bulk tissue data, or an external expression atlas; the source text does not report those methodological specifics.
The correlation between expression and enrichment does not establish directionality. The cohort-level data indicate association; mechanistic experiments will be required to test whether binding causally increases damage formation or blocks repair at particular positions within motifs.
Mutational-signature analysis in the cohort implicated a heterogeneous set of processes acting at enriched binding-site positions. Investigators reported involvement not only of UV-associated damage (expected in melanoma) but also of signatures tied to age-associated processes, cytosine deamination, oxidative damage, and tobacco exposure. These signature assignments indicate that TF-associated enrichment can arise from diverse forms of DNA damage and repair failure, and that the underlying mutagenic mechanism may vary by cancer type and by TF.
The abstract does not enumerate the exact signature names or the relative contributions of each signature at individual TF positions; readers should consult the full paper for the detailed signature decomposition and per-site attributions.
Authors emphasized that enrichment often occurred at specific nucleotide positions within TF motifs rather than uniformly across the entire binding site. The catalog therefore reports position-level resolution of mutation enrichment, enabling prioritization of particular bases within motifs for functional follow-up. Because the analysis accounted for local and sequence-context background rates, the position-specific signals represent deviations beyond expected sequence-intrinsic mutability.
Position-focused signals varied by tissue and by TF cluster. The abstract indicates a heterogeneous pattern: some TFs showed enrichment at a narrow set of positions, while other TF clusters had broader or different positional patterns. The source text does not list which exact motif positions or which TF clusters had the strongest signals in the abstract.
The resource integrates somatic mutation calls across a large tumor cohort and annotates TF binding motifs grouped into motif clusters. Analyses were performed at single-nucleotide resolution and corrected for sequence-dependent and local background mutation rates, according to the authors. The work yields a pan-cancer catalog tying specific TFs and motif positions to mutation enrichment and pairing those positions with candidate mutational processes via signature analysis.
The abstract does not provide full methodological parameters in the text provided here; for example, it does not state the exact statistical tests, multiple-testing correction approach, or the criteria used to group motifs into clusters. Those methodological specifics are available in the full manuscript and supplementary material.
The authors framed the catalog as a roadmap for experimental assessment of TF-induced mutagenesis and for interpretation of noncoding mutations in cancer. The abstract acknowledges that mechanistic validation is required to determine whether TF binding causes increased damage formation, blocks repair, or both. It also implies that the specific mutagenic processes implicated by signature analysis will need targeted experimental follow-up in relevant tissue contexts.
Limitations apparent from the abstract include the absence of peer review (the article is a preprint) and incomplete reporting of methodological thresholds and per-cluster sample sizes within the abstract itself. The authors did not report experimental validation within the abstract; therefore, the catalog should be interpreted as a hypothesis-generating resource until functional work confirms causal mechanisms.